Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BiomX (PHGE)
:PHGE
Earnings Data
Report Date
Mar 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-1.1Last Year’s EPS
-0.6Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 14, 2020
|% Change Since: 1.39%
|Next Earnings Date:Mar 26, 2020
Earnings Call Sentiment|Positive
The earnings call presented a mix of positive developments and challenges. Key achievements include completing patient enrollment for a crucial trial and securing additional funding, along with a net income turnaround. However, manufacturing delays and increased expenses pose challenges. Despite these issues, the company's positive clinical results and financial runway provide a strong outlook.Company Guidance
During the BiomX Q3 2024 earnings call, the company provided several key metrics and updates regarding their clinical pipeline and financial status. BiomX announced the completion of patient enrollment for the Phase II trial of BX211 targeting diabetic foot osteomyelitis (DFO), with top-line results expected in Q1 2025. They highlighted that the U.S. Defense Health Agency has contributed $36.8 million in funding for this trial. The company also addressed a manufacturing delay for BX004, a treatment for chronic lung infections in cystic fibrosis patients, which pushed the Phase IIb study results to the first half of 2026. Financially, BiomX reported a cash balance of $24.7 million as of September 30, 2024, and a net income of $9.6 million for the quarter, reflecting non-cash income from warrant revaluation. The company also noted increased R&D expenses due to trial preparations and a goodwill impairment expense of $801,000 related to their March 2024 acquisition of Adaptive Phage Therapeutics.Completion of Patient Enrollment for BX211 Phase II Trial
BiomX completed patient enrollment for the BX211 Phase II trial, with top line results expected in the first quarter of 2025. This trial focuses on diabetic foot osteomyelitis (DFO) associated with Staphylococcus aureus.
Additional Funding from U.S. Defense Health Agency
The U.S. Defense Health Agency provided additional funding this past quarter, bringing total nondilutive funding for the DFO trial to $36.8 million.
Positive Clinical Data for BX004
Positive safety and efficacy results from the BX004 Phase Ib/IIa trial were presented at key scientific conferences, showing a significant portion of patients achieved sputum culture conversion to negative for Pseudomonas aeruginosa.
Net Income Turnaround
BiomX reported a net income of $9.6 million for the third quarter of 2024, compared to a net loss of $7.9 million in the same period of 2023, primarily due to noncash income from warrant revaluation.
Sufficient Cash Runway
BiomX's cash reserves are sufficient to fund operations into the fourth quarter of 2025, following a $50 million private placement financing in March 2024.
---
PHGE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PHGE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $0.72 | $0.75 | +4.17% |
| Aug 15, 2024 | $1.84 | $1.63 | -11.41% |
| May 21, 2024 | $3.42 | $3.65 | +6.73% |
| Apr 03, 2024 | $3.84 | $3.50 | -8.85% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does BiomX (PHGE) report earnings?
BiomX (PHGE) is schdueled to report earning on Mar 26, 2025, TBA Not Confirmed.
What is BiomX (PHGE) earnings time?
BiomX (PHGE) earnings time is at Mar 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PHGE EPS forecast?
PHGE EPS forecast for the fiscal quarter 2024 (Q4) is -1.1.
---